BioNTech SE (BNTX) Monday announced a sharp fall in third-quarter earnings compared to the prior year, as the commercial revenues were down sharply. The company revised down its COVID-19 vaccine revenues for the full year 2023.
The quarterly earnings were 160.6 million euros or 0.67 cents, down from 1.784 billion euros or 6.98 cents in the prior year. On average, 2 analysts polled by Thomson Reuters were looking for earnings of $0.62 per share. Analysts' views usually exclude special items.
Revenue for the quarter declined to 895.3 million euros from 3.461 billion euros a year ago. Commercial revenues were 893.7 million euros, down from 3.394 billion last year. R&D expenses surged to 497.9 million from 341.8 million euros in the prior year.
For the full year 2023, the company now expects COVID-19 vaccine revenues to be 4 billion euros compared to its March outlook of 5 billion euros. Research and Development expenses are now projected to be in the range of 1.8 to 2.00 billion euros, while the March projection was in the range of 2.4 to 2.6 billion euros.
Currently, in the Nasdaq pre-market, shares are at $98.86, up 3.22 percent from the previous close of $92.49.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.